Lifespan extension therapy: Glyburide, an anti- hyperglycemic medication,   increases life span via up-regulation of its target gene BubR1, 9/October/2016, 11.18 pm

Molecular therapy for Non-alcoholic fatty liver disease (NAFLD): Isoflurane [Trade name: Forane] promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 09/October/2017, 11.10 am
October 9, 2017
Antiviral therapy for chikungunya (CHIKV) and Zika (ZIKV) viruses: A pharmaceutical mixture encompassing Artesunate and 15-Deoxy-Delta-12,14-prostaglandin J2 (15d-PGJ2) [APGJ2] increases spermidine/spermine N1-acetyltransferase (SAT) expression, depletes spermidine and Spermine levels, and restricts Chikungunya and Zika viruses replication via up regulation of its target gene, 09/October/2017, 11.29 pm
October 9, 2017
Show all

 What they say: Introduction: 

A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July  2014 issue of the journal  “EMBO”, by Prof Sinclair, North BJ, and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Lifespan extension therapy: Glyburide, an anti- hyperglycemic medication,   increases life span via up-regulation of its target gene BubR1

price-100


What is known? 

Nateglinide is an anti-hyperglycemic medication prescribed to treat TIIDM. However, the mechanism of action is far from clear. I had published earlier that Nateglinide may improve insulin sensitivity, promote resistance to bone, immune and motor dysfunction and  extend lifespan through down regulation of p70 S6 Kinase.


From Research Findings to Therapeutic Opportunity: 

This study suggests, for the first time, a role for Glyburide in lifespan extension. Glyburideby increasing the expression of its target gene, it may: (a) increase the expression of BuBR1; and (b) decrease the expression of p70 S6 Kinase.

Figure 1. Glyburide, an antihyperglycemic medication, may extend  mammalian life span via up regulation of BuBR1 and down regulation of p70 S6 Kinase

Thereby, it may: (1) delay diseases of aging; (2) slow down aging; and (3) prolong median life span. Thus, pharmacological formulations encompassing “Glyburide or its analogues, either alone or in combination with other drugs” may be used to extend the lifespan of an individual (fig. 1).


Details on the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $100#

Undisclosed mechanistic information: How Glyburide increases the expression of BubR1 and extends mammalian life-span

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

# Research cooperation


References

Web: http://genomediscovery.org or http://newbioideas.com

CitationBoominathan, L., Lifespan extension therapy: Glyburide, an anti- hyperglycemic medication,   increases life span via up-regulation of its target gene BubR1, 9/October/2016, 11.18 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.